Trial Profile
Study of concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy (pembrolizumab or nivolumab)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 18 May 2018 New trial record